Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy of Dolutegravir Plus Lamivudine Compared to Dolutegravir Plus Tenofovir/Emtricitabine in HIV-1-infected Treatment-naïve Adults Without Baseline Genotyping Test (D2ARLING Study)

NCT04549467 is registered in ClinicalTrials.gov with Fundacion IDEAA as lead sponsor.

NCT NCT04549467
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04549467 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy of Dolutegravir Plus Lamivudine Compared to Dolutegravir Plus Tenofovir/Emtricitabine in HIV-1-infected Treatment-naïve Adults Without Baseline Genotyping Test (D2ARLING Study)
Lead sponsor
Fundacion IDEAA
Phase
Phase 4
Overall status
Completed
Start date
November 17, 2020
Completion date
September 30, 2023
Enrollment
244 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hiv, hiv-1-infection